SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 4 — Sick Visit — Lorraine Hansberry

PatientLorraine Hansberry
Date of birth1993-05-19
IdentifiersMRN HR-ML034-SYN; SSN (made up) 000-34-7158
Document date2026-07-16
AuthorOdette Marchetti-Fields, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Watery diarrhea since yesterday, three days after chemotherapy. [S]

History of Present Illness

Ms. Hansberry called the oncology line on day 4 of her fifth cycle of modified FOLFIRINOX and was seen the same day. The pump was disconnected two days ago and pegfilgrastim given. Since yesterday afternoon she has had six watery stools, two of them overnight, and mild cramping. She took loperamide 4 mg at the first loose stool and 2 mg after each one since, eight tablets in all. Her stools are not pale or greasy as they were before pancrelipase, and there is no blood or black stool. She has had no fever (highest 37.2 °C at home), vomiting, or antibiotics, and no one around her is ill. She feels light-headed when she stands and has been drinking less than usual because of the cramps. She is eating little. Her blood glucose readings at home have been 110 to 150 mg/dL. She was writing every morning last week and wants to be back at her desk by the weekend. She has had no thoughts of self-harm. [S]

ElementDetail
OnsetYesterday afternoon, on day 3 of cycle 5
SeveritySix watery stools a day above her usual; cramping; no blood
ContextIrinotecan late diarrhea is expected two to ten days after a dose; pegfilgrastim given two days ago
Treatment so farLoperamide 4 mg, then 2 mg after each loose stool: eight tablets
Associated signs and symptomsLight-headed on standing; no fever, vomiting, blood, or antibiotic use

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired and light-headed on standing; no fever or chills
GastrointestinalPositiveWatery diarrhea and cramping; no blood, black stool, or vomiting
GenitourinaryPositivePassing less urine than usual
CardiovascularNegativeNo chest pain or leg swelling
EndocrineNegativeHome glucose 110 to 150 mg/dL; no low readings
PsychiatricNegativeFrustrated at losing writing days; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfastOne tablet daily before breakfastOral route2026-04-20activeS
Ferric carboxymaltose 50 mg/mL injection, 750 mg intravenously, two doses one week apart750 mg intravenously; two doses one week apartIntravenous route2026-04-24 to 2026-05-01completedS
Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for painOne tablet every 4 hours as neededOral route2026-05-04activeS
Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodoneTwo tablets at nightOral route2026-05-04activeS
Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snackTwo capsules with each meal, one with each snackOral route2026-05-04 to 2026-10-05completedS
Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-27completedS
Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5Day 1 every 14 days, cycles 1 to 5Intravenous route2026-05-18 to 2026-07-13completedS
Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cyclesDay 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-27completedS
Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus46-hour infusion from day 1 every 14 days for six cyclesIntravenous route2026-05-18 to 2026-07-29completedS
Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected6 mg on day 3 of each cycleSubcutaneous route2026-05-20 to 2026-07-29completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route2026-05-18activeS
Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycleOne tablet at night on days 1 to 4Oral route2026-05-18activeS
Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed4 mg at onset, then 2 mg after each loose stoolOral route2026-05-18activeS
Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgeryOne tablet twice dailyOral route2026-06-29 to 2026-08-21completedS
Potassium chloride 20 mEq extended-release tablet, two tablets by mouth today, then one tablet daily for three days40 mEq today, then 20 mEq daily for three daysOral route2026-07-16 to 2026-07-19completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-07-16Body height163cmS
2026-07-16Body weight53.6kgS
2026-07-16Body mass index (BMI) [Ratio]20.2kg/m2S
2026-07-16Systolic blood pressure98mm[Hg]S
2026-07-16Diastolic blood pressure62mm[Hg]S
2026-07-16Heart rate104/minS
2026-07-16Respiratory rate16/minS
2026-07-16Body temperature37.1CelS
2026-07-16Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-07-16Hemoglobin [Mass/volume] in Blood11g/dL12-15.5 g/dLLowS
2026-07-16Leukocytes [#/volume] in Blood by Automated count6.210*3/uL4-11 10*3/uLNormalS
2026-07-16Neutrophils [#/volume] in Blood by Automated count4.110*3/uL1.5-7.7 10*3/uLNormalS
2026-07-16Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
2026-07-16Sodium [Moles/volume] in Serum or Plasma134mmol/L135-145 mmol/LLowS
2026-07-16Potassium [Moles/volume] in Serum or Plasma3.2mmol/L3.5-5.1 mmol/LLowS
2026-07-16Creatinine [Mass/volume] in Serum or Plasma0.94mg/dL0.59-1.04 mg/dLNormalS
2026-07-16Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M83mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-07-16Glucose [Mass/volume] in Serum or Plasma118mg/dL70-99 mg/dLHighS
2026-07-16Magnesium [Mass/volume] in Serum or Plasma1.6mg/dL1.7-2.2 mg/dLLowS

Physical Exam

Vital signs recorded on 2026-07-16; see the Vital Signs section. [S]

SystemFinding
GeneralTired but alert; weight 53.6 kg, down 1.2 kg from the weight at cycle 4; temperature 37.1 °C
Vital signsLying 104/66 with pulse 96; standing 96/60 with pulse 112 and light-headedness: orthostatic
Head, eyes, ears, nose, and throatDry mouth; no mouth sores
AbdomenSoft, mildly tender in the lower abdomen without guarding; active bowel sounds; no distension
SkinPort site clean; no jaundice

Problems

ProblemClinical statusVerificationCodeProvenance
Epigastric pain for about two months, boring through to the back and worse after meals and lying flat, with nausea, early fullness, a loss of 5 kg (8 percent of her weight), and pale, loose stools: an upper abdominal cause such as a bleeding ulcer or a pancreatic or duodenal tumor must be found. Upper endoscopy and pancreas-protocol CT booked this weekresolvedconfirmed R10.13S — Synthetic presenting problem anchored to the documented collapse in pain and the account of a suspected duodenal ulcer. Superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic upper gastrointestinal blood loss: black stools on and off for three weeks, two near-fainting spells, hemoglobin 9.1 g/dL, MCV 74 fL, ferritin 6 ng/mLactiveconfirmed D50.0S — Synthetic finding anchored to the documented account that she was told she had anemia and bleeding ulcers.
New hyperglycemia: A1c 6.6% and random glucose 132 mg/dL in a lean woman of 32 who is losing weight; new diabetes with weight loss can be the first sign of a pancreatic cancer, so it is to be confirmed and explained, not labeled type 2resolvedconfirmed R73.09S — Synthetic finding; superseded when diabetes due to the pancreatic cancer was recorded at the second visit.
Adenocarcinoma of the head of the pancreas, 3.1 cm, invading the duodenum, borderline resectable (tumor contact of more than half the circumference of the superior mesenteric vein, no arterial contact), no distant spread, CA 19-9 486 U/mL after biliary drainage; on EUS-guided biopsy; synthetic modern detail linked to her documented cancer, whose primary site the sources record differentlyactiveconfirmed C25.0S — Synthetic histology, site, stage and course; the sources say she died of cancer and differ on whether it was pancreatic, duodenal, or colonic with spread to the pancreas (R). See sources.md.
Diabetes due to the pancreatic cancer (pancreatogenic, type 3c): A1c 6.6% at intake and fasting glucose 141 mg/dLactiveconfirmed E08.9S — Synthetic consequence of the synthetic tumor.
Exocrine pancreatic insufficiency from obstruction of the pancreatic duct: pale, floating, loose stools after fatty meals and weight lossactiveconfirmed K86.81S — Synthetic consequence of the synthetic tumor; diagnosed clinically, as guidance allows in pancreatic cancer.
Cancer-related pain in the upper abdomen and back, 6 out of 10, with sleep broken by itactiveconfirmed G89.3S — Synthetic symptom of the synthetic tumor.
Obstruction of the distal common bile duct by the tumor, relieved by a covered metal stent placed at ERCPactiveconfirmed K83.1S — Synthetic consequence of the synthetic tumor.
Chemotherapy-induced diarrhea from irinotecan, grade 2 (five to six watery stools a day above her usual), starting on day 3 of cycle 5, with low potassium and magnesium and mild dehydration; no fever, blood or neutropenia; resolvedactiveconfirmed K52.1S — Synthetic treatment effect; not a historical claim.
Oxaliplatin peripheral neuropathy, grade 1: tingling in the fingers and toes in the cold, lasting a few days after each cycle, with mild tingling at the fingertips between cycles; no effect on writing or buttonsactiveconfirmed G62.0S — Synthetic common effect of oxaliplatin.

Assessment and Plan

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026); Benson AB 3rd, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004;22(14):2918-2926 (PMID 15254061) (2004)

Follow-up: Phone call tomorrow morning and blood test (potassium, magnesium, creatinine) in two days. Cycle 6 as booked if recovered. Next scheduled visit 2026-08-10: after six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomy. [S]